Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin Bremer

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Molecular Cancer|November 25, 2010
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivoMarco de Bruyn, Anna A Rybczynska, Yunwei Wei, et al.
Oncoimmunology|July 3, 2015
CD20<sup>+</sup> T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancerMarco de Bruyn, Valerie R Wiersma, Maartje C A Wouters, et al.
The Journal of Investigative Dermatology|May 11, 2012
The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cellsValerie R Wiersma, Marco de Bruyn, Robert J van Ginkel, et al.
International Journal of Molecular Sciences|January 24, 2019
The Biophysical Interaction of the Danger-Associated Molecular Pattern (DAMP) Calreticulin with the Pattern-Associated Molecular Pattern (PAMP) LipopolysaccharideUnnati M Pandya, Chinaza Egbuta, Trefa M Abdullah Norman, et al.
Cancer Research|April 19, 2005
Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7Edwin Bremer, Douwe F Samplonius, Matthias Peipp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2011
Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cellsMarco de Bruyn, Yunwei Wei, Valerie R Wiersma, et al.
Molecular Therapy. Oncology|July 1, 2025
K12-ligand-based CAR T cell therapy for CD7-positive T cell malignanciesNienke Visser, Macarena González-Corrales, Jimena Álvarez-Freile, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 9, 2026
Selective Targeting of Immune Checkpoints HLA-G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer ImmunityLisa J Jacob, Liat Tamir, Mufeed Abdeen, et al.
Nature Communications|February 3, 2019
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosisYuan He, Renee Bouwstra, Valerie R Wiersma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2020
Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical TrialShuhong Wang, Yusheng Lin, Xiao Xiong, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Molecular Cancer|November 25, 2010
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivoMarco de Bruyn, Anna A Rybczynska, Yunwei Wei, et al.
Oncoimmunology|July 3, 2015
CD20<sup>+</sup> T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancerMarco de Bruyn, Valerie R Wiersma, Maartje C A Wouters, et al.
The Journal of Investigative Dermatology|May 11, 2012
The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cellsValerie R Wiersma, Marco de Bruyn, Robert J van Ginkel, et al.
International Journal of Molecular Sciences|January 24, 2019
The Biophysical Interaction of the Danger-Associated Molecular Pattern (DAMP) Calreticulin with the Pattern-Associated Molecular Pattern (PAMP) LipopolysaccharideUnnati M Pandya, Chinaza Egbuta, Trefa M Abdullah Norman, et al.
Cancer Research|April 19, 2005
Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7Edwin Bremer, Douwe F Samplonius, Matthias Peipp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2011
Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cellsMarco de Bruyn, Yunwei Wei, Valerie R Wiersma, et al.
Molecular Therapy. Oncology|July 1, 2025
K12-ligand-based CAR T cell therapy for CD7-positive T cell malignanciesNienke Visser, Macarena González-Corrales, Jimena Álvarez-Freile, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 9, 2026
Selective Targeting of Immune Checkpoints HLA-G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer ImmunityLisa J Jacob, Liat Tamir, Mufeed Abdeen, et al.
Nature Communications|February 3, 2019
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosisYuan He, Renee Bouwstra, Valerie R Wiersma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2020
Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical TrialShuhong Wang, Yusheng Lin, Xiao Xiong, et al.
Pageof 10